Fibrinolytic therapy, also termed thrombolytic therapy, is a medical strategy designed to dissolve blood clots within the vascular system. The formation of blood clots, or thrombi, poses significant health threats by obstructing blood vessels and giving rise to conditions like pulmonary embolism or deep vein thrombosis. Utilizing fibrinolytic agents, such as tissue plasminogen activator (tPA), this intervention facilitates the breakdown of fibrin, a key protein in blood clot formation. The administration of fibrinolytic therapy is particularly time-critical, especially in acute scenarios such as pulmonary embolism, where prompt action can prevent or mitigate severe consequences. Despite its effectiveness, fibrinolytic therapy is not without risks, with potential complications including bleeding. Consequently, its application is judiciously weighed against individual patient factors and the specific clinical context. As medical research advances, ongoing exploration seeks to refine approaches, aiming to improve the safety and efficacy of fibrinolytic therapy, contributing to the continual enhancement of vascular care.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Preservation of Skeletal Muscle Mass During GLP 1 Receptor Agonist Mediated Weight Loss Clinical Determinants Risk Stratification and Evidence Based Mitigation Strategies
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : A Unique Case of Infective Endocarditis: Staphylococcus lugdunensis Infective Endocarditis Presenting as Embolic Occipital Stroke Due to Posterior Mitral Leaflet Perforation
Nuha Hasnain, Royal Preston Hospital, United Kingdom
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation